Aquila Diagnostics is pleased to announce they have been selected to present at the third annual Venture Summit West in Mountain View California, on February 28-March 1. The Summit, presented by youngStartup Ventures, is a premier industry gathering connecting venture capitalists, corporate VCs, angel investors, technology transfer professionals, senior executives of early stage and emerging growth companies, university researchers, incubators and service providers.
Aquila was selected to present as one of 10 promising early stage life science companies at the conference. Aquila is raising funds to launch its innovative molecular diagnostic test platform into the north American veterinarian market.
Brent James, Aquila’s CEO will present the Aquila investment opportunity to the conference on the morning of March 1st. Jason Acker, Aquila CTO will also be in attendance.
About Aquila Diagnostic Systems Inc.
Aquila Diagnostic Systems Inc. (Aquila) is an Edmonton based company developing the Accutastm, a hydrogel based point of care molecular diagnostic system. The hydrogel matrix contains all of the reagents for performing highly sensitive diagnostic tests at the point of care.
Aquila will launch its patented molecular (DNA/RNA) diagnostic technology in the large North American and European markets for companion animal (canine and feline) care. What differentiates Aquila’s technology is the ability to offer this gold-standard testing, with sample-to-results in one-to-two hours, in the veterinarian’s clinic. By performing testing at the point-of-care, the current practice of sending samples to remote laboratories for testing and waiting 48-72 hours to receive results can be eliminated, allowing for treatment to be initiated faster.
What further differentiates the Aquila technology is its application to dramatically improve the quality of high-volume diagnostic tests in veterinary clinics. Moving molecular diagnostic testing from off–site centralized laboratories into a veterinary clinic is disruptive. Replacing insensitive and high volume visual inspection and antibody tests with gold-standard molecular diagnostic tests is game-changing.
Aquila’s technology provides a significant competitive advantage in the veterinary animal health diagnostic testing market. The worldwide market for the first 12 products on Aquila’s product roadmap is an estimated $2.0 billion.
For more information on Aquila please visit www.aquiladiagnostics.com
Aquila Contact: Mr. Brent James, CEO, email@example.com